Physician profile
Gary A Tarshis
NPI 1861436503
$10,167.93
in general payments reported to CMS, 2019-2025
24 companies · $2,220 in 2025
The $2,220 reported for 2025 was more than what 96% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,112 · 2021: $11.35 · 2022: $49.15 · 2023: $2,626 · 2024: $2,150 · 2025: $2,220.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $4,401 · Food and Beverage: $2,595.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $4,400.64 |
| Food and Beverage | $2,595.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Uk Limited | $2,467.38 | 2019 | |
| Merck Sharp & Dohme LLC | $2,435.31 | 2023 | |
| Genentech USA, INC. | $2,299.47 | 2024-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,131.76 | 2025 | |
| Genzyme Corporation | $336.19 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $248.37 | 2019 | |
| Janssen Biotech, INC. | $224.44 | 2023-2025 | Tremfya, Stelara |
| Genentech, INC. | $184.53 | 2019 | |
| Pfizer INC. | $122.79 | 2019-2025 | |
| Abbvie INC. | $115.76 | 2022-2025 | |
| Ardelyx, INC. | $112.26 | 2023-2025 | Ibsrela |
| Janssen Scientific Affairs, LLC | $103.13 | 2019 | |
| Madrigal Pharmaceuticals | $93.28 | 2025 | Rezdiffra |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $63.07 | 2021-2025 | Xifaxan |
| Regeneron Healthcare Solutions, INC. | $61.06 | 2024-2025 | Dupixent |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $47.63 | 2025 | |
| Intercept Pharmaceuticals, INC. | $30.75 | 2022 | |
| Nestle Healthcare Nutrition INC. | $20.89 | 2023 | |
| Qol Medical, LLC | $18.91 | 2025 | Sucraid |
| Takeda Pharmaceuticals U.S.A., INC. | $18.03 | 2025 | Eohilia |
| Ferring Pharmaceuticals INC. | $16.84 | 2023 | Rebyota |
| Aimmune Therapeutics, INC. | $16.08 | 2025 | Zenpep |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gary Tarshis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.